Related Experiment Video

Updated: Jun 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled

Lei Zhang1, Shuning Zhang, Hong Jiang

  • 1Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Shanghai Medical College of Fudan University, Shanghai, China.

Archives of Medical Research
|November 4, 2010
PubMed

Insights

Statins may help reduce certain inflammation markers in chronic heart failure (CHF) patients, specifically high-sensitivity C-reactive protein and soluble vascular cell adhesion molecule-1. However, effects on other markers like interleukin-6 were not significant.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Inflammation plays a key role in the progression of chronic heart failure (CHF).
  • The impact of statin therapy on inflammation markers in CHF patients is not fully understood.
  • This meta-analysis investigates the role of statins in modulating inflammation in CHF.

Purpose of the Study:

  • To evaluate the effect of statin therapy on key inflammation markers in patients with chronic heart failure.
  • To synthesize evidence from randomized controlled trials on statins and inflammation in CHF.
  • To identify potential factors influencing statin efficacy on inflammation markers.

Main Methods:

  • A systematic search of major databases (PubMed, MEDLINE, EMBASE, EBM Reviews) was conducted.
  • Randomized controlled trials comparing statin and non-statin treatments in CHF patients were included.
  • Standardized mean differences were calculated using random effects models to pool data from 10 studies involving 6052 patients.

Main Results:

  • Statin therapy significantly reduced high-sensitivity C-reactive protein (SMD = -0.74) and soluble vascular cell adhesion molecule-1 (SMD = -0.49).
  • No significant reduction was observed for interleukin-6 (SMD = -0.85) or tumor necrosis factor-α (SMD = -0.13).
  • Subgroup analyses indicated that age, etiology, ejection fraction, statin type, and follow-up duration may influence statin effects.

Conclusions:

  • Statin therapy demonstrates a partial suppressive effect on specific inflammatory markers in CHF patients.
  • The beneficial impact of statins on inflammation may vary based on statin type, treatment duration, and patient characteristics.
  • Further research may elucidate optimal statin strategies for managing inflammation in CHF.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...